• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与异羟肟酸抑制剂复合的基质金属蛋白酶-2催化结构域的溶液结构和主链动力学

Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor.

作者信息

Feng Yiqing, Likos John J, Zhu Leiming, Woodward Harold, Munie Grace, McDonald Joseph J, Stevens Anna M, Howard Carol P, De Crescenzo Gary A, Welsch Dean, Shieh Huey Sheng, Stallings William C

机构信息

Discovery Research, Pharmacia Corporation, 700 Chesterfield Parkway North, St. Louis, MO 63017, USA.

出版信息

Biochim Biophys Acta. 2002 Jul 29;1598(1-2):10-23. doi: 10.1016/s0167-4838(02)00307-2.

DOI:10.1016/s0167-4838(02)00307-2
PMID:12147339
Abstract

MMP-2 is a member of the matrix metalloproteinase family that has been implicated in tumor cell metastasis and angiogenesis. Here, we describe the solution structure of a catalytic domain of MMP-2 complexed with a hydroxamic acid inhibitor (SC-74020), determined by three-dimensional heteronuclear NMR spectroscopy. The catalytic domain, designated MMP-2C, has a short peptide linker replacing the internal fibronectin-domain insertion and is enzymatically active. Distance geometry-simulated annealing calculations yielded 14 converged structures with atomic root-mean-square deviations (r.m.s.d.) of 1.02 and 1.62 A from the mean coordinate positions for the backbone and for all heavy atoms, respectively, when 11 residues at the N-terminus are excluded. The structure has the same global fold as observed for other MMP catalytic domains and is similar to previously solved crystal structures of MMP-2. Differences observed between the solution and the crystal structures, near the bottom of the S1' specificity loop, appear to be induced by the large inhibitor present in the solution structure. The MMP-2C solution structure is compared with MMP-8 crystal structure bound to the same inhibitor to highlight the differences especially in the S1' specificity loop. The finding provides a structural explanation for the selectivity between MMP-2 and MMP-8 that is achieved by large inhibitors.

摘要

基质金属蛋白酶-2(MMP-2)是基质金属蛋白酶家族的成员,与肿瘤细胞转移和血管生成有关。在此,我们描述了通过三维异核核磁共振光谱法测定的与一种异羟肟酸抑制剂(SC-74020)复合的MMP-2催化结构域的溶液结构。该催化结构域称为MMP-2C,有一个短肽接头取代了内部纤连蛋白结构域插入序列,且具有酶活性。当排除N端的11个残基时,距离几何模拟退火计算得出14个收敛结构,其主链和所有重原子相对于平均坐标位置的原子均方根偏差(r.m.s.d.)分别为1.02 Å和1.62 Å。该结构具有与其他MMP催化结构域相同的整体折叠,并且与先前解析的MMP-2晶体结构相似。在溶液结构和晶体结构之间观察到的差异,出现在S1'特异性环底部附近,似乎是由溶液结构中存在的大抑制剂诱导产生的。将MMP-2C溶液结构与结合相同抑制剂的MMP-8晶体结构进行比较,以突出特别是在S1'特异性环中的差异。这一发现为大抑制剂实现的MMP-2和MMP-8之间的选择性提供了结构解释。

相似文献

1
Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor.与异羟肟酸抑制剂复合的基质金属蛋白酶-2催化结构域的溶液结构和主链动力学
Biochim Biophys Acta. 2002 Jul 29;1598(1-2):10-23. doi: 10.1016/s0167-4838(02)00307-2.
2
High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.人胶原酶-3(基质金属蛋白酶-13)催化片段与异羟肟酸抑制剂复合物的高分辨率溶液结构。
J Mol Biol. 2000 Sep 22;302(3):671-89. doi: 10.1006/jmbi.2000.4082.
3
NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound.人成纤维细胞胶原酶催化片段与异羟肟酸化合物的磺酰胺衍生物复合后的核磁共振溶液结构。
Biochemistry. 1999 Jun 1;38(22):7085-96. doi: 10.1021/bi982576v.
4
Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.人巨噬细胞弹性蛋白酶(基质金属蛋白酶-12)与异羟肟酸抑制剂复合物的晶体结构
J Mol Biol. 2001 Sep 28;312(4):743-51. doi: 10.1006/jmbi.2001.4953.
5
Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1.与一种强效非肽磺酰胺抑制剂复合的人胶原酶-3(基质金属蛋白酶-13)催化结构域的溶液结构:与基质溶解素-1和胶原酶-1的结合比较
J Mol Biol. 2000 Aug 11;301(2):513-24. doi: 10.1006/jmbi.2000.3988.
6
A novel series of highly selective inhibitors of MMP-3.一系列新型的基质金属蛋白酶-3高选择性抑制剂。
Bioorg Med Chem Lett. 2007 Dec 15;17(24):6750-3. doi: 10.1016/j.bmcl.2007.10.042. Epub 2007 Oct 17.
7
High-resolution solution structure of the inhibitor-free catalytic fragment of human fibroblast collagenase determined by multidimensional NMR.通过多维核磁共振确定的人成纤维细胞胶原酶无抑制剂催化片段的高分辨率溶液结构。
Biochemistry. 1998 Feb 10;37(6):1495-504. doi: 10.1021/bi972181w.
8
Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.基于异羟肟酸的基质金属蛋白酶2肽抑制剂
Biochimie. 2005 Mar-Apr;87(3-4):385-92. doi: 10.1016/j.biochi.2004.09.008.
9
Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.明胶酶催化结构域的同源性建模及新型磺胺类抑制剂的对接模拟
J Med Chem. 1999 May 20;42(10):1723-38. doi: 10.1021/jm980514x.
10
Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453.人基质溶解素-1(MMP-3)和胶原酶-3(MMP-13)催化结构域与异羟肟酸抑制剂SM-25453的晶体结构
Biochem Biophys Res Commun. 2006 May 26;344(1):315-22. doi: 10.1016/j.bbrc.2006.03.098. Epub 2006 Mar 27.

引用本文的文献

1
In-silico study of rosmarinic acid roles in inhibiting breast cancer progression.迷迭香酸在抑制乳腺癌进展中作用的计算机模拟研究
Biomedicine (Taipei). 2025 Mar 1;15(1):23-30. doi: 10.37796/2211-8039.1638. eCollection 2025.
2
Repurposing ProTAME for Bladder Cancer: A Combined Therapeutic Approach Targeting Cell Migration and MMP Regulation.将ProTAME用于膀胱癌治疗:一种针对细胞迁移和基质金属蛋白酶调节的联合治疗方法。
Biology (Basel). 2025 Mar 5;14(3):263. doi: 10.3390/biology14030263.
3
Comprehensive Bioactive Compound Profiling of Leaves: LC-MS/MS Analysis, Antioxidant Potential, and Molecular Insights.
叶片中生物活性化合物的综合分析:液相色谱-串联质谱分析、抗氧化潜力及分子见解
Drug Des Devel Ther. 2025 Feb 18;19:1195-1213. doi: 10.2147/DDDT.S507658. eCollection 2025.
4
Synthesis and Characterization of a New Class of Chromene-Azo Sulfonamide Hybrids as Promising Anticancer Candidates with the Exploration of Their EGFR, CAII, and MMP-2 Inhibitors Based on Molecular Docking Assays.新型香豆素偶氮磺酰胺杂合体的合成与表征:基于分子对接研究其作为有前景的抗癌候选物的 EGFR、CAII 和 MMP-2 抑制剂
Int J Mol Sci. 2023 Nov 24;24(23):16716. doi: 10.3390/ijms242316716.
5
An Amino Acid Substitution in Elongation Factor EF-G1A Alters the Antibiotic Susceptibility of Pseudomonas aeruginosa LasR-Null Mutants.延伸因子 EF-G1A 中的一个氨基酸取代改变了铜绿假单胞菌 LasR 缺失突变体对抗生素的敏感性。
J Bacteriol. 2023 Jun 27;205(6):e0011423. doi: 10.1128/jb.00114-23. Epub 2023 May 16.
6
Outlook on Chronic Venous Disease Treatment: Phytochemical Screening, In Vitro Antioxidant Activity and In Silico Studies for Three Vegetal Extracts.展望慢性静脉疾病的治疗:三种植物提取物的植物化学成分筛选、体外抗氧化活性和计算机模拟研究。
Molecules. 2023 Apr 23;28(9):3668. doi: 10.3390/molecules28093668.
7
Carborane-Containing Hydroxamate MMP Ligands for the Treatment of Tumors Using Boron Neutron Capture Therapy (BNCT): Efficacy without Tumor Cell Entry.含硼烷的羟肟酸 MMP 配体用于硼中子俘获治疗(BNCT)治疗肿瘤:无需肿瘤细胞进入即可发挥疗效。
Int J Mol Sci. 2023 Apr 9;24(8):6973. doi: 10.3390/ijms24086973.
8
Synergistic effects of dendrosomal nanocurcumin and oxaliplatin on oncogenic properties of ovarian cancer cell lines by down-expression of MMPs.树状纳米姜黄素与奥沙利铂通过下调 MMPs 表达对卵巢癌细胞系致癌特性的协同作用。
Biol Res. 2023 Jan 20;56(1):3. doi: 10.1186/s40659-023-00412-x.
9
Rational synthesis, anticancer activity, and molecular docking studies of novel benzofuran liked thiazole hybrids.新型苯并呋喃类似噻唑杂合体的合理合成、抗癌活性及分子对接研究。
Mol Divers. 2023 Jun;27(3):1345-1357. doi: 10.1007/s11030-022-10493-7. Epub 2022 Jul 19.
10
Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management.筛选一组局部眼科药物对 MMP-2 和 MMP-9 的作用,以研究其在圆锥角膜管理中的潜力。
Molecules. 2022 Jun 2;27(11):3584. doi: 10.3390/molecules27113584.